会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 68. 发明申请
    • PROCESS FOR PRODUCING 2-(DIALKYLOXY METHYL)-CARBOXYLIC ACID ESTERS
    • 2-(二烷基甲基) - 羧酸酯的制备方法
    • WO1992012116A1
    • 1992-07-23
    • PCT/EP1991002388
    • 1991-12-12
    • HOECHST AKTIENGESELLSCHAFTSTRUTZ, Heinz
    • HOECHST AKTIENGESELLSCHAFT
    • C07C69/708
    • C07C67/31C07C69/708
    • Process for producing 2-(dialkyloxy methyl)-carboxylic acid esters of formula (I) in which: R is a non-aromatic hydrocarbon radical or a heterocyclic non-aromatic radical which, besides O, N and/or S atoms, contains only C and H atoms in the ring, with 1 to 20 C atoms, where radical R can accept 1 to 5 substituents and the substituents may be the same or different and are halogen, an aryl, carbalkoxy, dialkylamino, diarylamino or cyano group or an alkoxy group, where the alkyl is substituted or unsubstituted C1 to C12-alkyl, or an aryloxy group, where the aryl is substituted or unsubstituted C6 to C14-aryl, a substituted or unsubstituted benzyl or phenethyl radical or an R O-(R O)x-R group, where R is substituted or unsubstituted C1 to C12-alkyl or C6 to C14-aryl, R is a branched or unbranched hydrocarbon radical with 1 to 4 C atoms or phenylene and x = 1 to 6, R is hydrogen or alkyl with 1 to 5 C atoms, and R is unsubstituted or substituted C6 to C14-aryl or a radical listed under R , by the oxidising beta acetalisation of acrylic acid esters with R OH alcohols, where R has the significance given, in the presence of oxygen as the oxidising agent and a catalyst system based on one or more metals of the platinum group and/or their compounds and a copper compound, in which the reaction is conducted at a temperature of up to 80 DEG C and the catalyst system contains 1 to 4 equivalent anions related to the sum of the metal atoms and cations, of which at most 3 are equivalent halide ions, where the halogen has a molecular weight of at least 35.
    • 制备式(I)的2-(二烷基氧基甲基) - 羧酸酯的方法,其中:R 1是非芳族烃基或杂环非芳族基团,除了O,N和/或S原子 在环中仅含有C和H原子,具有1至20个C原子,其中基团R 1可以接受1至5个取代基,取代基可以相同或不同,为卤素,芳基,烷氧羰基,二烷基氨基, 二芳基氨基或氰基或烷氧基,其中烷基是取代或未取代的C1至C12-烷基或芳氧基,其中芳基是取代或未取代的C6至C14-芳基,取代或未取代的苄基或苯乙基或 R 4 O-(R 5 O)x R 5基团,其中R 4是取代或未取代的C 1至C 12 - 烷基或C 6至C 14 - 芳基,R 5是支链或非支链烃 具有1至4个C原子或亚苯基且x = 1至6的基团,R 2为氢或具有1至5个C原子的烷基,R 3为未取代的或取代的C 6至C 14 - 芳基或 在R 1所列的基团中,通过丙烯酸酯与R 1 OH醇的氧化β-缩醛化,其中R 1在氧气作为氧化剂存在下具有重要性,并且基于 一种或多种铂族金属和/或其化合物的金属和铜化合物,其中反应在高达80℃的温度下进行,并且催化剂体系含有与金属之和相关的1至4当量阴离子 原子和阳离子,其中至多3是相当的卤离子,其中卤素的分子量至少为35。
    • 70. 发明申请
    • THE USE OF ANTIBODIES TO TNF OR FRAGMENTS DERIVED THEREOF AND XANTHINE DERIVATIVES FOR COMBINATION THERAPY AND COMPOSITIONS THEREFOR
    • 抗体对TNF或其衍生物的片段的使用和用于组合治疗的Xanthine衍生物及其组合物
    • WO1992007585A1
    • 1992-05-14
    • PCT/GB1991001907
    • 1991-10-30
    • CELLTECH LIMITEDHOECHST AKTIENGESELLSCHAFTANAGNOSTOPULOS, HiristoGEBERT, UlrichHANEL, HeinzLIMBERT, MichaelBODMER, Mark, WilliamHIGGS, Gerald, Anthony
    • CELLTECH LIMITEDHOECHST AKTIENGESELLSCHAFT
    • A61K39/395
    • A61K39/395A61K31/52A61K2300/00
    • A combined preparation for simultaneous combined, simultaneous separate, or sequential use in the therapy or prophylaxis of disorders associated with undesirably high levels of TNF, e.g. septic or endotoxic shock and immunoregulatory and inflammatory disorders, which comprises an antibody to TNF or a TNF binding fragment thereof and a xanthine derivative. Particular preferred xanthine derivatives are 3,7-dimethyl-1-(5-oxo-hexyl)xanthine (known as Pentoxifylline or Trental) and 1-(5-hydroxy-5-methylhexyl)-3-methylxanthine and similar compounds. The anti-TNF antibody or fragment is preferably monospecific especially a humanised recombinant antibody or fragment. The ratio of xanthine derivative to anti-TNF antibody component used may be in the range between 450:1 and 1:10 and doses of anti-TNF component in the range 0.001-30mg/kg/day and doses of xanthine derivative in the range 0.5 to 100mg/kg/day may be administered during treatment of human or animal subjects. It has been found that when an anti-TNF antibody and a xanthine derivative are used together in some experimental models of septic shock, a surprising combination effect is observed.
    • 用于同时组合,同时分开或顺序使用的联合制剂,用于治疗或预防与不期望的高水平的TNF相关的病症,例如, 脓毒性或内毒素性休克和免疫调节性和炎症性疾病,其包含TNF抗体或其TNF结合片段和黄嘌呤衍生物。 特别优选的黄嘌呤衍生物是3,7-二甲基-1-(5-氧代 - 己基)黄嘌呤(称为己酮可可碱或特伦塔尔)和1-(5-羟基-5-甲基己基)-3-甲基黄嘌呤和类似化合物。 抗TNF抗体或片段优选是单特异性的,特别是人源化的重组抗体或片段。 黄嘌呤衍生物与抗TNF抗体组分的比例可以在450:1至1:10的范围内,抗TNF成分的剂量范围为0.001-30mg / kg /天,黄嘌呤衍生物的剂量范围为 在人或动物受试者的治疗期间可以施用0.5至100mg / kg /天。 已经发现,当在一些感染性休克的实验模型中一起使用抗TNF抗体和黄嘌呤衍生物时,观察到惊人的组合效应。